Objective To evaluate the effects of saxagliptin on β cell function of type 2 diabetic patients.
Methods The Cochrane Library, PubMed, EMbase, CBM, VIP, and CNKI were searched from their establishment to November, 2011, for relevant randomized controlled trials on the effects of saxagliptin on β cell function in type 2 diabetic patients. Language was limited to Chinese and English only. Two reviewers independently screened the literature according to the inclusion and exclusion criteria, extracted the data, and evaluated and cross-checked the methodological quality. Then meta-analysis was conducted using RevMan 5.0 software.
Results Five RCTs were included. The results of meta-analysis showed that: HOMA-B was significantly increased in the saxagliptin (or saxagliptin plus routine treatment) 2.5 mg, 5 mg, and 10 mg groups (MD=8.03, 95%CI 4.57 to 11.48, P lt;0.000 01; MD=7.50, 95%CI 4.27 to 10.73, P lt;0.000 01; MD=17.45, 95%CI 13.93 to 20.97, P lt;0.000 01); HOMA-IR was similar between saxagliptin 2.5 or 10 mg group, and control group (MD= –0.05, 95%CI –0.18 to 0.08, P=0.47; MD= –0.18, 95%CI –0.60 to 0.24, P=0.4).
Conclusion Current evidence shows that saxagliptin is effective in improving β cell function and insulin resistance. Due to short follow-up and small sample size, this conclusion has to be further proved by more high-quality RCTs.
Citation：
LING Xuemei,YANG Chunxia. Effect of Saxagliptin on the β-cell Function of Patients with Type 2 Diabetes: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2013, 13(4): 436-440. doi: 10.7507/1672-2531.20130075
Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
叶山东. 糖尿病诊断治疗学. 第1版. 合肥: 安徽科学技术出版社, 2000: 15.
|
| 2. |
叶林秀, 郭昆全, 杨茂平, 等. 老年2型糖尿病患者氧化应激状态与β细胞功能的研究. 中国老年学杂志, 2009, 29(24): 3292-3293.
|
| 3. |
Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy, 2010, 30(5): 463-484.
|
| 4. |
Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook. org.
|
| 5. |
Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes, Obesity And Metabolism, 2008, 10(5): 376-386.
|
| 6. |
Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes:A Randomised Controlled Trial. Int J Clin Pract, 2009, 63(9): 1395-1406.
|
| 7. |
DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxzgliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care, 2009, 32(9): 1649-1655.
|
| 8. |
Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab, 2009, 94(12): 4810-4819.
|
| 9. |
Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin, 2009, 25(10): 2401-2411.
|
| 10. |
叶兴蓉, 王炜, 孙海清, 等. 老年2型糖尿病患者体重指数与胰岛β细胞功能及胰岛素抵抗相关性的探讨. 华西医学, 2009, 24(4): 885-886.
|
| 11. |
National Institute for health and clinical excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. NICE short clinical guideline 87. London: NICE, 2009.
|
| 12. |
陆菊明. 2型糖尿病治疗新药沙格列汀的药理及临床评价. 中国新药杂志. 2011, 20(21): 2039-2043.
|
| 13. |
Henry RR, Smith SR, Schwartz SL, et al. Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes. Diabetes Obes Metab, 2011, 13(9): 850-858.
|
- 1. 叶山东. 糖尿病诊断治疗学. 第1版. 合肥: 安徽科学技术出版社, 2000: 15.
- 2. 叶林秀, 郭昆全, 杨茂平, 等. 老年2型糖尿病患者氧化应激状态与β细胞功能的研究. 中国老年学杂志, 2009, 29(24): 3292-3293.
- 3. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy, 2010, 30(5): 463-484.
- 4. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook. org.
- 5. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes, Obesity And Metabolism, 2008, 10(5): 376-386.
- 6. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes:A Randomised Controlled Trial. Int J Clin Pract, 2009, 63(9): 1395-1406.
- 7. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxzgliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care, 2009, 32(9): 1649-1655.
- 8. Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab, 2009, 94(12): 4810-4819.
- 9. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin, 2009, 25(10): 2401-2411.
- 10. 叶兴蓉, 王炜, 孙海清, 等. 老年2型糖尿病患者体重指数与胰岛β细胞功能及胰岛素抵抗相关性的探讨. 华西医学, 2009, 24(4): 885-886.
- 11. National Institute for health and clinical excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. NICE short clinical guideline 87. London: NICE, 2009.
- 12. 陆菊明. 2型糖尿病治疗新药沙格列汀的药理及临床评价. 中国新药杂志. 2011, 20(21): 2039-2043.
- 13. Henry RR, Smith SR, Schwartz SL, et al. Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes. Diabetes Obes Metab, 2011, 13(9): 850-858.
